HOUSTON - s4story -- UK healthcare innovator, RD Biomed, developed Peptest, the world's first non-invasive test for reflux, in 2007.  Since that time it has grown to global prominence. Shipping costs and wait times were a barrier to the U.S. market preventing the adoption of this direct to consumer diagnostic test. Now with Restech managing the PepsinCheck operations, the test is shipped from the U.S., processed at strategically located American labs, and results are sent back to the consumer by mail and a secure email within about a week.

Both PepsinCheck (U.S. market) and Peptest (non-U.S. markets) are manufactured by RD Biomed to the same global standard. The test detects the presence of the stomach enzyme pepsin (recognized as a reliable diagnostic biomarker for reflux) in saliva and sputum samples.

Restech VP of Clinical Affairs, Thomas Ball, commented, "As we Rethink Reflux across the continuum of care, direct to consumer healthcare plays a pivotal role.  RD Biomed and the Peptest provide an ideal accompaniment to our product portfolio, ensuring that tough diagnostic cases find appropriate physician-based care in addition to broadening our reach to an unprecedented range of patients. PepsinCheck represents the first at-home reflux testing in the US market and holds the potential to revolutionize the care of individuals with symptoms ranging from heartburn, to chronic cough, and even obstructive sleep apnea."

More on S For Story

• $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
• $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
• Indies United is pleased to present our July 2025 book releases
• New Book Music Care: The Bridge to Hope Explores Music as a Lifeline Through Life's Hardships
• Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers

Professor Peter Dettmar, Director of RD Biomed, said: "We're thrilled that our salivary pepsin test for diagnosing reflux has officially launched in the US. It has been a pleasure working with Restech, a successful digestive health solutions company, and we could not have chosen a better company to distribute and commercialise PepsinCheck by Peptest."

About Restech

At Restech, we believe there is a better way to manage reflux. Our team designed and launched the first real-time sensor that could function highly accurately in a non-liquid environment. Since then, we've obsessed over reflux, developing and seeking out new products across the diagnostic and therapeutic continuum. www.restech.com

About RD Biomed & Peptest

RD Biomed is a pharmaceutical development and diagnostic company based at Castle Hill Hospital in Hull, East Yorkshire. Innovators in healthcare product development, RD Biomed focusses on gastroenterology and wound management and develops products that identify, prevent and treat various medical conditions.  www.peptest.co.uk

More on S For Story

• Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
• Industry Insider Unveils Groundbreaking Car Buying Guide for First-Time Buyers:
• Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
• Twentieth Century Publications Helps Authors Turn Ideas Into Published Success Stories
• Award-Winning Author Debuts New E-Book

CONTACTS

Thomas Ball
Vice President of Clinical Affairs
T: 1.800.352.1512
E: tball@restech.com

Harvey Dettmar
Director, RD Biomed Limited
T: +44 1482 461866
E: harvey.dettmar@technostics.com

www.pepsincheck.com